SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care
AboutOpen · 07.07.2026 · 13 (1) · 31-41
DOI: 10.33393/ao.2026.3728 ↗Kurz gefasst
Fachartikel in der Zeitschrift AboutOpen, online erschienen am 07.07.2026. Verfasst von Raffaela Giachero und 35 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The management of transplant-eligible, newly diagnosed multiple myeloma is evolving with the adoption of antiCD38-based quadruplet regimens and the potential earlier use of anti-BCMA CAR T-cell therapy in lenalidomiderefractory disease. In this context, the national macroregional syMMphony project (covering Northern, Central, and Southern Italy) was developed to coordinate clinical and organizational pathways across the continuum of care, from initial autologous stem cell transplantation (ASCT) to referral for CAR T-cell therapy. The project involved structured multidisciplinary discussions within three Italian macroareas focused on four key areas: the impact of anti-CD38 quadruplets, criteria for ASCT eligibility, early identification of patients who may qualify for CAR T-cell therapy based on CARTITUDE-4, and organizational requirements for equitable access to advanced treatments. Each macroarea produced written agreements, which were then compared and harmonized during a national plenary meeting to create a final cross-regional consensus. Across all macroareas, ASCT remained central, with eligibility based mainly on overall fitness rather than age alone, and tandem transplantation reserved for select high-risk cases. Daratumumab combined with lenalidomide maintenance was recognized as an emerging post-transplant strategy, while MRD-guided modulation appeared promising but required methodological standardization and the establishment of dedicated laboratory networks. Early referral pathways for CAR T-cell therapy were increasingly seen as relevant for certain patients with lenalidomide-refractory relapse, highlighting the importance of hub-and-spoke models, resource planning, sustainable funding, and systematic collection of real-world data. Overall, the syMMphony project produced a macroregional agreement aimed at supporting more consistent and timely care pathways, aligned with evolving evidence and regulatory frameworks.
Zitieren
APA
Giachero, R., Botta, C., Bramanti, S., Buda, G., Toritto, T. C. D., Cea, M., Cetani, G., Vià, M. C. D., D'Agostino, M., Novellis, D. D., Pepa, R. D., Derudas, D., Furlan, A., Gamberi, B., Giaccone, L., Grillo, G., Liberatore, C., Mancuso, K., Mangiacavalli, S., …, & Finocchiaro, C. Y. (2026). SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care. AboutOpen, 13(1), 31-41. https://doi.org/10.33393/ao.2026.3728
Vancouver
Giachero R, Botta C, Bramanti S, Buda G, Toritto TCD, Cea M, et al. SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care. AboutOpen. 2026;13(1):31-41. doi:10.33393/ao.2026.3728
BibTeX
@article{Giachero2026,
author = {Giachero, Raffaela and Botta, Cirino and Bramanti, Stefania and Buda, Gabriele and Toritto, Tommaso Caravita di and Cea, Michele and Cetani, Giusy and Vià, Matteo Claudio Da and D'Agostino, Mattia and Novellis, Danilo De and Pepa, Roberta Della and Derudas, Daniele and Furlan, Anna and Gamberi, Barbara and Giaccone, Luisa and Grillo, Giovanni and Liberatore, Carmine and Mancuso, Katia and Mangiacavalli, Silvia and Marcacci, Giampaolo and Martino, Massimo and Mele, Anna and Mele, Giuseppe and Offidani, Massimo and Paris, Laura and Patriarca, Francesca and Petrucci, Maria Teresa and Rocco, Stefano and Romano, Alessandra and Rossi, Elena and Rossini, Bernardo and Scalone, Renato and Sica, Simona and Tinelli, Martina and Zambello, Renato and Finocchiaro, Claudia Yvonne},
title = {SyMMphony - From transplant-eligible newly diagnosed multiple myeloma to second-line CAR-T cell therapy: harmonizing treatment pathways to improve care},
journal = {AboutOpen},
year = {2026},
volume = {13},
number = {1},
pages = {31--41},
doi = {10.33393/ao.2026.3728}
}
EUVIMED